Acute precipitants of congestive heart failure exacerbations

被引:226
作者
Tsuyuki, RT
McKelvie, RS
Arnold, JMO
Avezum, A
Barretto, ACP
Carvalho, ACC
Isaac, DL
Kitching, AD
Piegas, LS
Teo, KK
Yusuf, S
机构
[1] Univ Alberta, Epidemiol Coordinating & Res Ctr EPICORE, Div Cardiol, Edmonton, AB T6G 2S2, Canada
[2] McMaster Univ, Div Cardiol, Hamilton, ON, Canada
[3] Dante Pazzanese Cardiol Inst, Sao Paulo, Brazil
[4] Univ Sao Paulo, Med Sch Hosp, Inst Heart, Sao Paulo, Brazil
[5] Univ Fed Sao Paulo, Paulista Sch Med, Sao Paulo, Brazil
[6] Univ Calgary, Div Cardiol, Calgary, AB, Canada
关键词
D O I
10.1001/archinte.161.19.2337
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Few studies have prospectively and systematically explored the factors that acutely precipitate exacerbation of congestive heart failure (CHF) in patients with left ventricular dysfunction. Knowledge of such factors is important in designing measures to prevent deterioration of clinical status. The objective of this study was to prospectively describe the precipitants associated with exacerbation of CHF status in patients enrolled in the Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study. Methods: We conducted a 2-stage, multicenter, randomized trial in 768 patients with CHF who had an ejection fraction of less than 40%. Patients were randomly assigned to receive enalapril maleate, candesartan cilexetil, or both for 17 weeks, followed by randomization to receive metoprolol succinate or placebo for 26 weeks. Investigators systematically documented information on clinical presentation, management, and factors associated with the exacerbation for any episode of acute CHF during follow-up. Results: A total of 323 episodes of worsening of CHF occurred in 180 patients during 43 weeks of follow-up; 143 patients required hospitalization, and 5 died. Factors implicated in worsening of CHF status included noncompliance with salt restriction (22%); other noncardiac causes (20%), notably pulmonary infectious processes; study medications (15%); use of antiarrhythmic agents in the past 48 hours (15%); arrhythmias (13%); calcium channel blockers (13%); and inappropriate reductions in CHF therapy (10%). Conclusions: A variety of factors, many of which are avoidable, are associated with exacerbation of CHF. Attention to these factors and patient education are important in the prevention of CHF deterioration.
引用
收藏
页码:2337 / 2342
页数:6
相关论文
共 18 条
[1]  
ACKMAN ML, 1998, CAN J CARDIOL SF, V14, pF130
[2]  
BOURASSA MG, 1993, J AM COLL CARDIOL S, V22, P14
[3]   Factors contributing to the hospitalization of patients with congestive heart failure [J].
Chin, MH ;
Goldman, L .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1997, 87 (04) :643-648
[4]   Utilization and dosing of angiotensin-converting enzyme inhibitors for heart failure - Effect of physician specialty and patient characteristics [J].
Chin, MH ;
Wang, JC ;
Zhang, JX ;
Lang, RM .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1997, 12 (09) :563-566
[5]   Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy -: The randomized evaluation of strategies for left ventricular dysfunction pilot study [J].
Cirillo, W ;
Decanini, R ;
Coelho, OR ;
Avezum, A ;
Peixoto, MSP ;
Piegas, LS ;
Neto, JMR ;
Paiva, M ;
Carvalho, AC ;
de Almeida, DR ;
Fernandes, IML ;
Malavasi, MC ;
Pavanello, R ;
Canesin, M ;
Ishii, S ;
Barretto, ACP ;
Imrie, J ;
Moore, R ;
Woo, K ;
Bernstein, V ;
Mizgala, HF ;
Mooney, S ;
Hilbich, D ;
Kuritzky, R ;
Rupka, DW ;
Blackwell, MM ;
Breakwell, L ;
Kornder, JM ;
Pearce, SA ;
Polasek, P ;
Richardson, PM ;
Grant, J ;
Isaac, D ;
Beresford, P ;
Giannoccaro, P ;
Roth, D ;
Greenwood, P ;
Muzyka, T ;
Prosser, A ;
Brass, N ;
Hui, W ;
Kvill, L ;
Goeres, M ;
MacDonald, K ;
Senaratne, M ;
Hill, L ;
Humen, D ;
Teo, KK ;
Habib, N ;
Habib, N .
CIRCULATION, 2000, 101 (04) :378-384
[6]   PRECIPITATING FACTORS LEADING TO DECOMPENSATION OF HEART-FAILURE - TRAITS AMONG URBAN BLACKS [J].
GHALI, JK ;
KADAKIA, S ;
COOPER, R ;
FERLINZ, J .
ARCHIVES OF INTERNAL MEDICINE, 1988, 148 (09) :2013-2016
[7]  
GRAVES EJ, 1995, 1993 SUMMARY NATL HO
[8]   CLINICAL CHARACTERISTICS OF PATIENTS IN STUDIES OF LEFT-VENTRICULAR DYSFUNCTION (SOLVD) [J].
JOHNSTONE, D ;
LIMACHER, M ;
ROUSSEAU, M ;
LIANG, CS ;
EKELUND, L ;
HERMAN, M ;
STEWART, D ;
GUILLOTTE, M ;
BJERKEN, G ;
GAASCH, W ;
HELD, P ;
VERTER, J ;
STEWART, D ;
YUSUF, S .
AMERICAN JOURNAL OF CARDIOLOGY, 1992, 70 (09) :894-900
[9]   Comparison of candesartan, enalapril, and their combination in congestive heart failure - Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study - The RESOLVD pilot study investigators [J].
McKelvie, RS ;
Yusuf, S ;
Pericak, D ;
Avezum, A ;
Burns, RJ ;
Probstfield, J ;
Tsuyuki, RT ;
White, M ;
Rouleau, J ;
Latini, R ;
Maggioni, A ;
Young, J ;
Pogue, J .
CIRCULATION, 1999, 100 (10) :1056-1064
[10]   The pharmacoeconomics of ACE inhibitors in chronic heart failure [J].
McMurray, J ;
Davie, A .
PHARMACOECONOMICS, 1996, 9 (03) :188-197